Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
Given possible lack of benefit findings in subset analysis of Monarch 3, would you still use Abemaciclib in a postmenopausal woman with high-risk ER+ breast cancer?
Related Questions
For patients with HbA1c >6 can the INAVO regimen still be utilized if the patient is otherwise fit and has a strategy for ongoing glycemic control?
At what time points during a patient's treatment for metastatic ER+ breast cancer are you checking liquid NGS for endocrine pathway alterations?
Is there benefit of cold-cap use while patient is on sacituzumab-govitecan?
How would you approach a patient with metastatic high grade neuroendocrine carcinoma of the breast which is HR+ HER2 negative?
What adjuvant therapy would you offer a postmenopausal with a new pT2N0 HR+/HER2+ breast cancer primary who is concurrently being treated for well controlled oligometastatic HR+/HER2- who’s been on anastrozole/ribociclib?
In a patient with de novo stage IV breast carcinoma harboring an RB1 Q395* (nonsense) mutation, would treatment with a CDK4/6 inhibitor be appropriate, or should it be avoided due to likely resistance?
What supportive care measures do you prioritize to manage or prevent toxicity in patients receiving Dato-DXd?
How do you manage a symptomatic primary breast tumor in a patient with metastatic disease?
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
In patients with advanced HR+, HER2- breast cancer who have progressed on first-line CDK 4/6i and ET and found to have ESR1 mutation, are you offering combination of abemaciclib and elacestrant in the 2nd line or SERD monotherapy?
